| Not Yet Recruiting | To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence an NCT06315270 | The First Hospital of Jilin University | — |
| Recruiting | Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube C NCT05659381 | GOG Foundation | Phase 3 |
| Recruiting | Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian NCT05961124 | Sunnybrook Health Sciences Centre | Phase 2 |
| Recruiting | A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) NCT05429970 | Memorial Sloan Kettering Cancer Center | N/A |
| Recruiting | CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors NCT05410717 | Second Affiliated Hospital of Guangzhou Medical University | Phase 1 |
| Completed | Ask Questions (ASQ):Implementation of a Communication Intervention NCT05025748 | Barbara Ann Karmanos Cancer Institute | N/A |
| Recruiting | Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With A NCT04811703 | Hospices Civils de Lyon | Phase 1 |
| Active Not Recruiting | Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy NCT04204811 | Memorial Sloan Kettering Cancer Center | N/A |
| Unknown | Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites NCT04267575 | Jerome Canady, M.D. | N/A |
| Completed | 18F-DCFPyL PET/CT in High-grade Epithelial Ovarian Cancer (PET HOC) NCT03811899 | University Health Network, Toronto | N/A |
| Completed | Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovari NCT03188432 | Wake Forest University Health Sciences | Phase 2 |
| Withdrawn | PET Imaging of Ovarian Carcinoma With 18F-FSPG NCT02872519 | Vanderbilt-Ingram Cancer Center | EARLY_Phase 1 |
| Withdrawn | Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Perito NCT02833506 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian C NCT03297489 | Roswell Park Cancer Institute | EARLY_Phase 1 |
| Completed | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer NCT03154190 | Stanford University | N/A |
| Terminated | IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, o NCT03029611 | University of Washington | Phase 2 |
| Withdrawn | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery an NCT02567396 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving NCT00194714 | University of Washington | Phase 1 / Phase 2 |
| Completed | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations NCT02646319 | Mayo Clinic | EARLY_Phase 1 |
| Withdrawn | Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian NCT02470559 | Barbara Ann Karmanos Cancer Institute | Phase 1 |
| Terminated | Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis NCT02441140 | Dana-Farber Cancer Institute | N/A |
| Completed | Taking Care of Her Program in Patients With Stage III or IV Ovarian Cancer and Spouse Caregivers NCT02401321 | University of Washington | N/A |
| Completed | Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavi NCT02111941 | Mayo Clinic | EARLY_Phase 1 |
| Active Not Recruiting | HOT: HIPEC in Ovarian Cancer as Initial Treatment NCT02124421 | Mercy Medical Center | Phase 2 |
| Completed | Salvage Ovarian FANG™ Vaccine + Carboplatinum NCT01867086 | Gradalis, Inc. | Phase 2 |
| Unknown | Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer NCT01650376 | Swedish Medical Center | Phase 1 / Phase 2 |
| Completed | Interactive Educational Website for Women With Ovarian Cancer & Caregivers NCT01626014 | University of Minnesota | EARLY_Phase 1 |
| Completed | Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Pri NCT01606241 | Mayo Clinic | Phase 1 |
| Completed | Salvage Ovarian FANG™ Vaccine + Bevacizumab NCT01551745 | Gradalis, Inc. | Phase 2 |
| Completed | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors NCT01522820 | Roswell Park Cancer Institute | Phase 1 |
| Terminated | Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherap NCT01275664 | Gynecologic Oncology Group | N/A |
| Completed | Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stag NCT01196429 | National Cancer Institute (NCI) | Phase 2 |
| Completed | RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Canc NCT01175343 | National Cancer Institute (NCI) | Phase 2 |
| Completed | OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Ca NCT00857545 | Gynecologic Oncology Group | Phase 2 |
| Completed | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors NCT01131234 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritone NCT01080521 | Gynecologic Oncology Group | — |
| Completed | Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian NCT02311907 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Completed | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Isl NCT01010126 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithe NCT00814086 | Gynecologic Oncology Group | Phase 1 |
| Withdrawn | Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial NCT00551265 | Gynecologic Oncology Group | N/A |
| Terminated | YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal NCT00899093 | Gynecologic Oncology Group | — |
| Completed | Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopi NCT00301756 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, NCT00352300 | Gynecologic Oncology Group | Phase 1 |
| Completed | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian NCT00262847 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients NCT00316407 | Swedish Medical Center | Phase 1 / Phase 2 |
| Recruiting | Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovar NCT01000259 | Gynecologic Oncology Group | — |
| Completed | Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Pe NCT00072566 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ova NCT00066456 | Gynecologic Oncology Group | Phase 1 |
| Completed | Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopia NCT00060359 | Gynecologic Oncology Group | Phase 1 |
| Withdrawn | Research Study in Patients With Advanced Ovarian Epithelial Cancer NCT00053235 | Gynecologic Oncology Group | — |
| Completed | Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary NCT00011986 | Gynecologic Oncology Group | Phase 3 |
| Terminated | Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer NCT00003532 | Burzynski Research Institute | Phase 2 |
| Completed | Collecting Tumor Samples From Patients With Gynecological Tumors NCT00897442 | Gynecologic Oncology Group | — |